The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Impaired glucose tolerance, beta cell function and lipid metabolism in HIV patients under treatment with protease inhibitors
Abstract
OBJECTIVES: To evaluate metabolic abnormalities, beta-cell function, lipid profile and vascular risk factors in HIV patients on protease inhibitors (PI). DESIGN: Prospective cross-sectional study. METHODS: Thirty-eight HIV-1-infected patients receiving at least one PI were compared with 17 PI-naive HIV patients in an oral glucose tolerance test (OGTT). Serum glucose, insulin, proinsulin, and C-peptide were determined. The fasting lipid pattern was analysed using electrophoresis and the assessment of apolipoproteins including lipoprotein (a). Fibrinogen, homocysteine, and anticardiolipin antibodies were also assessed. RESULTS: Twenty-seven (71%) of the PI-treated group had detectable hyperlipidaemia. Isolated hypertriglyceridaemia was present in 12 patients (44%), two (7%) of them had type V and 10 (37%) subjects had type IV hyperlipidaemia (Frederickson classification). Type IIb hyperlipidaemia defined as an increase of both very-low-density lipoproteins (VLDL) and low-density lipoproteins (LDL) was found in 10 (36%) subjects, and five (18%) patients presented with isolated hypercholesterolaemia (type IIa). PI treatment was associated with significant higher fasting cholesterol, triglycerides, LDL and VLDL levels. Apolipoprotein B and E concentrations were significantly increased in patients receiving PI. Elevated concentrations of lipoprotein (a) (> 30 mg/dl) were detected in six (16%) of the hyperlipidaemic patients on PI. Eighteen (46%) patients on PI had impaired oral glucose tolerance and five (13%) had diabetes. Although four (24%) of the PI-naive patients were glucose intolerant, none had diabetes. Fasting concentrations and secretion response of insulin, proinsulin, and C-peptide to glucose ingestion was significantly increased in the PI-treated group suggesting a beta-cell dysfunction in addition to peripheral insulin resistance. Beta-cell abnormalities were associated with the abnormal lipid pattern and PI treatment. CONCLUSION: Combination drug regimens including PI are accompanied by impaired glucose tolerance, hyperproinsulinaemia as an indicator for beta-cell dysfunction, and lipid abnormalities proved to be significant risk factors for coronary heart disease. Moreover, PI may have an impact on the processing of proinsulin to insulin.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Carr, A., Samaras, K., Burton, S., Law, M., Freund, J., Chisholm, D. J., & Cooper, D. A. (1998) · AIDS · doi:10.1097/00002030-199807000-00003 · Cited by 2,370
Changing patterns of mortality across Europe in patients infected with HIV-1
Mocroft, A., Vella, S., Benfield, T., Chiesi, A., Miller, V, Gargalianos, P., Monforte, A. D., Yust, I., Bruun, J., Phillips, A., et al. (1998) · The Lancet · doi:10.1016/s0140-6736(98)03201-2 · Cited by 1,270
Carr, A., Samaras, K., Chisholm, D. J., & Cooper, D. A. (1998) · The Lancet · doi:10.1016/s0140-6736(98)03391-1 · Cited by 1,065
Grunfeld, C. (1992) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.74.5.1045 · Cited by 848
Visceral abdominal-fat accumulation associated with use of indinavir
Miller, K. D., Jones, E., Yanovski, J. A., Shankar, R., Feuerstein, I., & Falloon, J. (1998) · The Lancet · doi:10.1016/s0140-6736(97)11518-5 · Cited by 700
“Buffalo hump” in men with HIV-1 infection
Lo, J. C., Mulligan, K., Tai, V. W., Algren, H., & Schambelan, M. (1998) · The Lancet · doi:10.1016/s0140-6736(97)11443-x · Cited by 567
Walli, R., Herfort, O., Michl, G. M., Demant, T., Jäger, H., Dieterle, C., Bogner, J. R., Landgraf, R., & Goebel, F. D. (1998) · AIDS · doi:10.1097/00002030-199815000-00001 · Cited by 519
Severe premature coronary artery disease with protease inhibitors
Henry, K., Melroe, H., Huebsch, J., Hermundson, J., Levine, C., Swensen, L., & Daley, J. (1998) · The Lancet · doi:10.1016/s0140-6736(05)79053-x · Cited by 513
Tai, M. M. (1994) · Diabetes Care · doi:10.2337/diacare.17.2.152 · Cited by 498
Race, E. M., Adelson-Mitty, J., Kriegel, G. R., Barlam, T. F., Reimann, K. A., Letvin, N. L., & Japour, A. J. (1998) · The Lancet · doi:10.1016/s0140-6736(97)04352-3 · Cited by 358
Cited by
Guidelines for the Use of Antiretroviral Agents in HIV-Infected Adults and Adolescents
(1998) · Annals of Internal Medicine · doi:10.7326/0003-4819-128-12_part_2-199806151-00003 · Cited by 5,209
Friis-Møller, N., Weber, R., Reiss, P., Thiébaut, R., Kirk, O., Monforte, A. D., Pradier, C., Morfeldt, L., Mateu, S., Law, M., et al. (2003) · AIDS · doi:10.1097/00002030-200305230-00010 · Cited by 1,077
Yeni, P. G., Hammer, S. M., Carpenter, C. C. J., Cooper, D. A., Fischl, M. A., Gatell, J. M., Gazzard, B. G., Hirsch, M. S., Jacobsen, D. M., Katzenstein, D. A., et al. (2002) · JAMA · doi:10.1001/jama.288.2.222 · Cited by 709
Hadigan, C., Meigs, J. B., Corcoran, C., Rietschel, P., Piecuch, S., Basgoz, N., Davis, B., Sax, P., Stanley, T., Wilson, P. W. F., et al. (2001) · Clinical Infectious Diseases · doi:10.1086/317541 · Cited by 680
Impact of HIV infection and HAART on serum lipids in men
Riddler, S. A. (2003) · JAMA · doi:10.1001/jama.289.22.2978 · Cited by 624
Metadata
- Authors
- Behrens, G., Dejam, A., Schmidt, H., Balks, H.-J., Brabant, G., Körner, T., Stoll, M., & Schmidt, R. E.
- Venue
- AIDS
- Published
- 1999-07
- Volume
- 13
- Issue
- 10
- Pages
- F63-F70
- ISSN
- 0269-9370 (ISSN-L)
- OpenAlex
- W2007061978
- Cited by
- 515
- References
- 24
- FWCI
- 49.73
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Impaired glucose tolerance, beta cell function and lipid metabolism in HIV patients under treatment with protease inhibitors. https://app.cochat.ai/papers/10.1097/00002030-199907090-00001
- The paper
- Behrens, G., Dejam, A., Schmidt, H., Balks, H.-J., Brabant, G., Körner, T., Stoll, M., & Schmidt, R. E. (1999). Impaired glucose tolerance, beta cell function and lipid metabolism in HIV patients under treatment with protease inhibitors. AIDS. https://doi.org/10.1097/00002030-199907090-00001
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.